Tailored solutions can bridge critical gaps in clinical research and medical device design, driving equity for women and diverse populations.
For too long, the medical device industry has taken a one-size-fits-all approach to innovation, often neglecting the anatomical and physiological nuances of women and other underrepresented groups.
One of the many roots of this disparity runs back to the thalidomide tragedy of the 1960s, in which a morning sickness drug was linked to birth defects. Following public outcry, the FDA excluded women of childbearing age from clinical trials. This exclusion lingered for two decades, during which the majority of clinical research was conducted on male subjects, creating a systemic gap in data and understanding of women’s unique health needs.
Against this backdrop, leaders from across the medical device industry gathered at DeviceTalks West to discuss how the industry is tackling these inequities head-on.
Panelists included Dr. Jennifer Jones-McMeans, divisional VP of global clinical affairs at Abbott Vascular, who has pioneered efforts to enhance diversity in clinical trials; Hexagon Health CEO Dr. Shirin Towfigh, one of the few female hernia surgeons in the U.S., whose patented innovations are reshaping hernia repair; and Frontline Medical Technologies co-founder and CEO Dr. Asha Parekh, whose engineering expertise has driven the development of devices for critical care applications with specific focus on women’s anatomies.
Overcoming historical oversights in clinical trials
The historical lack of women in clinical trials has far-reaching consequences and has led to missed opportunities for improving care across all populations.
“Women present differently with cardiovascular disease symptoms. Their arteries are smaller, and their needs are often overlooked in design,” said Jones-McMeans.
Towfigh shared a particularly egregious example from her field. In hernia research, women were almost entirely excluded.
“There’s been about seven prospective randomized clinical trials for inguinal hernias. Over 10,000 patients enrolled, a total of 17 women. Only one of those trials had women. All the rest had zero,” she said. “That alone skews industry standards, skews what industry sees as how to design.”
This imbalance not only skews device performance data but also outcomes.
“The female pelvis is different, yet female patients are often misdiagnosed or underserved because the designs don’t reflect their needs,” Towfigh said.
Her patented hernia mesh redesigns aim to bridge this gap, reducing complications like chronic pain and dysfunction.
Parekh noted that while addressing the unique needs of women often highlights critical gaps in clinical trials, these innovations can ultimately benefit all patients.
“Our device is an aortic occlusion device, used specifically for postpartum hemorrhage,” she said. “Women have smaller arteries and pregnant women are susceptible to being hypercoagulable, so thrombosis is an issue. [But] it’s not just women in these emergency scenarios — men come into the emergency room too.”
To address these challenges, Parekh designed with these considerations in mind from the very beginning, prioritizing a smaller, minimally invasive device.
“We’re all trying to miniaturize minimally invasive [devices], everything as small and unobstructed as possible,” she said.
Starting with a focus on specific populations like women ensures that devices are better suited for all patients in the long run.
The role of representation in medical device design
Inclusive medical device design begins with diverse voices at the table. As one of the few female hernia surgeons, Towfigh said her practice sees a disproportionate number of female patients. This exposure gives her a unique lens to identify trends and unmet needs in her field.
“If I wasn’t here, who would notice these patterns?” she asked.
Parekh echoed the sentiment, saying, “Whether it’s engineers, clinicians, or trial participants, representation matters at every stage of development. You can’t design for a population you don’t truly understand.”
Abbott’s approach, as described by Jones-McMeans, involves both top-down and grassroots strategies. Abbott is intentionally recruiting more women for leadership roles in clinical trials and as investigators at clinical site, and made a concerted effort to ensure gender parity among study participants.
“We’ve partnered with organizations like Women as One to support female physicians and MedtechWomen to promote inclusivity,” she said. “Internally, we created a diversity and research office to ensure these priorities are embedded across our clinical trials.”
Investment in inclusive innovation
Funding remains a significant barrier to advancing gender-sensitive medical device design. Historically, investors have hesitated to fund devices tailored to smaller patient populations, often viewing them as niche markets. But this mindset is shifting.
”Many investors are simply unaware of the market opportunity until you present the data,” Parekh said, emphasizing the importance of using clinical and market data to build a compelling case during funding pitches.
Towfigh’s solution has been to self-fund her innovations, which isn’t always an option.
“It’s tough because you have to convince industry to invest money in a niche product … for a small proportion” of the population, she said.
Beyond gender and toward truly inclusive innovation
While much of the discussion focused on women, the broader goal is designing for diverse anatomies.
“Whether it’s pediatric patients, underserved ethnic groups, or individuals with unique physiological needs, personalized medicine is the future,” Parekh said.
Inclusive innovation — whether addressing women’s cardiovascular needs or designing for pediatric patients — has far-reaching benefits. But it won’t be achieved overnight, as systemic change takes sustained effort and collaboration.
“It’s a long game,” Jones-McMeans said. “The efforts we’re putting in now may not bear fruit until decades down the line. But maybe in 30 years, there’s a different group of women sitting here talking about the fruits of the work we’re doing today.”
Parekh was optimistic, given the growing momentum behind inclusive medical device design.
”I think we have come such a long way in terms of moving things forward for not just women but for diverse anatomies,” she said.
Towfigh shared in the optimism, emphasizing that progress comes through persistence and building a solid foundation of data. “You just have to keep pushing,” she said. “It takes time. People need to start hearing it over and over and over again, and you have to persist.”